Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz283.035
Abstract: Abstract Background Gastrointestinal stromal tumors (GISTs) patients (pts) who develop resistance to imatinib and sunitinib have few therapeutic options. Apatinib is a multiple tyrosine kinase inhibitor and targetsVEGFR2, PDGFRβ and c-Kit, which is effective in… read more here.
Keywords: apatinib; trial; efficacy safety; imatinib sunitinib ... See more keywords
Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.14185
Abstract: Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes that are involved in multiple cellular processes. Currently, multiple oral TKIs have been introduced in the treatment of solid tumours, all administered in… read more here.
Keywords: imatinib sunitinib; sunitinib pazopanib; pazopanib flat; fixed dosing ... See more keywords
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-3127
Abstract: Purpose: CDKN2A loss is frequent in gastrointestinal stromal tumors (GISTs) and associated with aggressive outcome. Palbociclib is a CDK4 inhibitor with preclinical antitumor efficacy in tumors with P16/CDKN2A loss. Patients and Methods: This is a… read more here.
Keywords: stromal tumors; patients advanced; imatinib sunitinib; palbociclib patients ... See more keywords
Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.11038
Abstract: 11038Background: We retrospectively collected data from metastatic Italian GIST patients treated with imatinib or sunitinib reintroduction after progression to conventional three or four lines of t... read more here.
Keywords: sunitinib regorafenib; imatinib sunitinib; advanced gist; gist progressing ... See more keywords
Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
Sign Up to like & getrecommendations! Published in 2017 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2017.00367
Abstract: Tyrosine kinase inhibitors (TKIs) are anticancer drugs with a lesser toxicity than classical chemotherapeutic agents but still with a narrow therapeutic window. While hepatotoxicity is known for most TKIs, underlying mechanisms remain mostly unclear. We… read more here.
Keywords: kinase inhibitors; glycolysis; imatinib sunitinib; toxicity ... See more keywords